Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice
Por:
Mariscal, A, Milan, M, Baucells, A, Martinez, MA, Guillen, AG, Trallero-Araguas, E, Alvarado-Cardenas, M, Martinez-Martinez, L, Alserawan, L, Franco-Leyva, T, Sanz-Martinez, MT, Vinas-Gimenez, L, Corominas, H, Juarez, C, Castellvi, I, Selva-O'Callaghan, A
Publicada:
1 feb 2021
Resumen:
Objectives
Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma.
Methods
We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay.
Results
A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline).
Conclusion
We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.
Filiaciones:
Mariscal, A:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Milan, M:
Hosp Santa Creu & Sant Pau, Rheumatol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Baucells, A:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Martinez, MA:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Guillen, AG:
Hosp Santa Creu & Sant Pau, Rheumatol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Trallero-Araguas, E:
Hosp Valle De Hebron, Rheumatol Unit, Barcelona, Spain
Alvarado-Cardenas, M:
Hosp Valle De Hebron, Internal Med Dept, Barcelona, Spain
Martinez-Martinez, L:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Alserawan, L:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Franco-Leyva, T:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Sanz-Martinez, MT:
Hosp Valle De Hebron, Immunol Dept, Barcelona, Spain
Vinas-Gimenez, L:
Hosp Valle De Hebron, Immunol Dept, Barcelona, Spain
Corominas, H:
Hosp Santa Creu & Sant Pau, Rheumatol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Juarez, C:
Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Castellvi, I:
Hosp Santa Creu & Sant Pau, Rheumatol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Selva-O'Callaghan, A:
Hosp Valle De Hebron, Internal Med Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Green Published, gold
|